- Research Article
1
- 10.22603/ssrr.2025-0124
Efficacy of Chemonucleolysis with Condoliase for Lumbar Disc Herniation in Elderly Patients Over 70 Years of Age
- Aug 09, 2025
- Spine Surgery and Related Research
- Tomohiro Banno + 9 more +9
Introduction Intradiscal therapy with condoliase is becoming one of the minimally invasive treatment options for lumbar disc herniation (LDH). However, evidence regarding its efficacy in elderly populations remains scarce. The purpose of this study is to reveal the efficacy of condoliase treatment for LDH in patients over the age of 70 years. Methods The patients with LDH who received condoliase treatment in our institution with a follow-up period of 1 year were enrolled in this study. The patients were divided into two groups according to age: group E (>70 years) and group C (20-70 years). To assess clinical outcomes, visual analog scale (VAS) scores for leg and back pain and the Oswestry Disability Index (ODI) were obtained. Disc height and degeneration were evaluated using magnetic resonance imaging. Treatment was considered effective if the VAS scores for leg pain improved by ≥50% at 1 year and surgery was avoided. Results A total of 121 patients were enrolled in the study. The therapy was effective in 12 of 17 patients (70.6%) in group E and 79 of 104 patients (76.0%) in group C. The deterioration rate of Pfirrmann grade was significantly higher in group C than in group E (53.9% vs. 7.1%). Improvements in VAS scores and ODIs were comparable between the two groups. There were no significant differences in disc height reduction or herniation reduction rates between the groups. Despite disc degeneration, herniation reduction was observed, accompanied by a decrease in disc height. Conclusions Chemonucleolysis with condoliase is effective in treating LDH in patients over 70 years of age, affording outcomes comparable to those in younger patients. Despite disc degeneration, herniation reduction was observed accompanied by a decrease in disc height. Condoliase offers a less invasive alternative for treating elderly patients with multiple comorbidities. Careful patient selection is critical for ensuring optimal clinical results.
Read more